Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease

Journal of Clinical Investigation

Volumn 117, Issue 11, 2007, Pages 3393-3402

  Wang, Jun ^a   Ho, Lap ^a,b   Chen, Linghong ^a   Zhao, Zhong ^a   Zhao, Wei ^a   Qian, Xianjuan ^a   Humala, Nelson ^a   Seror, Ilana ^a   Bartholomew, Sadie ^a   Rosendorff, Clive ^b   Pasinetti, Giulio Maria ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ALPRENOLOL; AMYLOID BETA PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; GANGLION BLOCKING AGENT; LABETALOL; LOOP DIURETIC AGENT; METOPROLOL TARTRATE; NADOLOL; PERINDOPRIL; PINDOLOL; POTASSIUM SPARING DIURETIC AGENT; PRACTOLOL; PRAZOSIN; PROPRANOLOL; THIAZIDE DIURETIC AGENT; TIMOLOL MALEATE; UNINDEXED DRUG; URAPIDIL; VALSARTAN; VASODILATOR AGENT;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG INDICATION; FEMALE; HYPERTENSION; LEARNING; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; SPATIAL MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIHYPERTENSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MEMORY; MICE; MICE, TRANSGENIC; PROTEIN STRUCTURE, QUATERNARY; RANDOM ALLOCATION; SPACE PERCEPTION; TETRAZOLES; VALINE;

EID: 36049002393     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31547     Document Type: Article

References (39)

1. Lopez-Arrieta, J.M., and Birks, J. 2002. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst. Rev. 3:CD000147.
2. Khachaturian, A.S., et al. 2006. Antihypertensive medication use and incident Alzheimer disease: the Cache County study. Arch. Neurol. 63:686-692.
3. Guo, Z.C., Viitanen, M., Winblad, B., and Fratiglioni, L. 1999. Low blood pressure and incidence of dementia in a very old sample: dependent on initial cognition. J. Am. Geriatr. Soc. 47:723-726.
4. Forette, F., et al. 2002. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 162:2046-2052.
5. in't Veld, B.A., Ruitenberg, A., Hofman, A., Stricker, B.H., and Breteler, M.M. 2000. Antihypertensive drugs and incidence of dementia: the Rotterdam study. Neurobiol. Aging. 54:A397.
6. Singer, R.B. 1991. Stroke in the elderly treated for systolic hypertension (SHEP). J. Insur. Med. 23:265-269.
7. Prince, M.J., Bird, A.S., Blizard, R.A., and Mann, A.H. 1996. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults. BMJ. 312:801-805.
8. Lithell, H., et al. 2004. The Study on Cognition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J. Hypertens. 22:1605-1612.
9. Selkoe, D.J. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:741-766.
10. Busciglio, J., Gabuzda, D.H., Matsudaira, P., and Yankner, B.A. 1993. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc. Natl. Acad. Sci. U. S. A. 90:2092-2096.
11. Haass, C., et al. 1992. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 359:322-325.
12. Shoji, M., et al. 1992. Production of the Alzheimer amyloid-beta protein by normal proteolytic processing. Science. 258:126-129.
13. Esch, F.S., et al. 1990. Cleavage of amyloid-beta peptide during constitutive processing of its precursor. Science. 248:1122-1124.
14. Walsh, D.M., et al. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:535-539.
15. Lesne, S., et al. 2006. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 440:352-357.
16. Kotilinek, L.A., et al. 2002. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22:6331-6335.
17. Jacobsen, J.S., et al. 2006. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 103:5161-5166.
18. Cleary, J.P., et al. 2005. Natural oligomers of the amyloid-[beta] protein specifically disrupt cognitive function. Nat. Neurosci. 8:79-84.
19. Klyubin, I., et al. 2005. Amyloid beta protein immunotherapy neutralizes A beta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11:556-561.
20. Mirjany, M., Ho, L., and Pasinetti, G.M. 2002. Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. J. Pharmacol. Exp. Ther. 301:494-500.
21. Klein, W.L. 2002. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41:345-352.
22. McLaurin, J., et al. 2002. Therapeutically effective antibodies against amyloid-[beta] peptide target amyloid-[beta] residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8:1263-1269.
23. Yamamoto, S., et al. 1997. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist - 1st communication: antihypertensive effects of valsartan in hypertensive models. Arzneimittelforschung. 47:604-612.
24. PDR.net. http://www.pdr.net.
25. Hsiao, K., et al. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:99-102.
26. Morris, R. 1984. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods. 11:47-60.
27. Morgan, D. 2005. Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener. Dis. 2:261-266.
28. Zhao, Z., et al. 2007. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol. Aging. 28:824-830.
29. Wang, J., et al. 2005. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J. 19:659-661.
30. Kawarabayashi, T., et al. 2001. Age-dependent changes in brain, CSF, and plasma amyloid {beta} protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21:372-381.
31. Takeda, K., et al. 2003. Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency. J. Endocrinol. 176:237-246.
32. McLaurin, J., et al. 2006. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 12:801-808.
33. Vallet, P.G., et al. 1992. A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease. Acta Neuropathologica. 83:170-178.
34. Ho, L., et al. 2004. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18:902-904.
35. Qiu, W.Q., et al. 1998. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273:32730-32738.
36. Zhao, Z., et al. 2005. Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance- associated promotion of Alzheimer's disease beta-amyloid neuropathology. FASEB J. 19:2081-2082.
37. Lopez-Ongil, S., et al. 2005. Crosstalk between mesangial and endothelial cells: angiotensin II down-regulates endothelin-converting enzyme 1. Cell. Physiol. Biochem. 15:135-144.
38. Takahashi, M., et al. 1995. Localization of rat endothelin-converting enzyme to vascular endothelial cells and some secretory cells. Biochem. J. 311:657-665.
39. Martindale. 2007. The complete drug reference. The Pharmaceutical Press. http://www.medicinescomplete.com/mc/martindale/current/contents.htm.